Lilly Licenses Zymeworks Technology to Develop Bi-specific Antibodies Genetic Engineering News Zymeworks has entered into a worldwide licensing and collaboration agreement with ImClone Systems, a wholly owned subsidiary of Eli Lilly, to develop a number of bi-specific antibody oncology therapeutics using Zymeworks' Azymetric™ platform. Zymeworks Announces $15.0 Million Private Placement Financing to Advance ... Zymeworks, ImClone Systems partner to develop novel bi-specific antibody ... |
